Takeda Pharmaceutical TAK Ratios (2017-2026)

NYSE TAK
$20.06 +0.45 (+2.29%)
As of: Oct 20, 2026 · 12:32 PM EDT
Reported Financials

Takeda Pharmaceutical Quarterly Ratios

Periods 35 quarters
Latest Jun 2026

Takeda Pharmaceutical reported a gross margin of 66.66% and a net margin of 9.28% for the quarter ended Jun 2026. These financial ratios cover 35 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Mar2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Nov2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
Gross Margin
74.59%68.78%69.88%71.66%213.21%58.95%69.67%66.08%67.50%63.60%67.96%64.71%66.04%63.73%67.96%70.63%66.04%62.93%66.66%66.66%
EBT Margin
23.48%8.01%22.93%15.99%6.44%9.77%14.69%12.76%10.18%4.56%11.31%11.31%8.00%-10.19%12.47%13.61%8.86%-41.57%13.34%13.34%
EBIT Margin
26.17%12.92%25.56%15.48%10.42%13.40%15.93%15.92%12.51%8.43%13.96%13.77%11.83%-7.11%15.28%16.68%11.97%-38.03%16.51%16.51%
EBITDA Margin
41.23%41.22%31.75%27.16%29.54%31.17%32.12%18.20%26.23%29.42%29.68%17.29%10.64%30.99%33.09%17.22%-20.61%29.94%29.88%
Operating Margin
26.17%12.92%25.56%15.48%10.42%13.40%15.93%15.92%12.51%8.43%13.96%13.77%11.83%-7.11%15.28%16.68%11.97%-38.03%16.51%16.51%
Net Margin
14.50%6.41%-1.17%10.80%6.16%10.86%9.92%8.44%8.90%2.96%7.88%7.88%5.98%-9.80%10.28%11.23%6.12%-33.67%10.18%9.28%
FCF Margin
20.71%16.93%12.99%24.97%37.54%4.55%13.07%7.37%18.42%-2.29%18.85%9.37%40.71%-10.81%23.80%11.86%37.91%-18.95%14.87%
Efficiency
Inventory AverageInventory Avg.
6,941.70M7,050.00M7,021.55M6,891.25M6,695.97M6,788.95M7,191.13M7,444.34M7,611.44M8,005.04M8,129.60M7,967.30M8,197.45M8,194.34M8,037.86M8,360.71M8,665.07M8,870.90M8,867.10M8,837.75M
Assets AverageAssets Avg.
115,784.37M112,435.13M109,179.70M105,487.11M101,992.69M101,306.21M103,195.21M103,480.51M100,880.00M100,075.69M100,166.39M100,378.45M101,526.68M99,144.49M95,728.56M96,068.97M97,143.31M97,947.09M97,778.37M96,888.09M
Equity AverageEquity Avg.
47,442.58M47,144.17M46,467.12M46,423.49M46,366.68M46,475.75M47,088.29M47,757.78M47,578.81M47,511.98M47,853.39M48,284.53M46,807.86M46,934.72M47,752.68M48,432.67M47,679.48M46,584.83M
Invested CapitalInvested Cap.
92,082.08M87,130.12M83,814.80M81,606.88M79,139.86M79,711.43M82,000.51M81,139.77M80,691.73M81,868.10M80,963.93M83,752.03M80,990.18M78,001.59M79,825.51M80,951.01M79,807.36M77,913.10M77,662.87M
Asset Utilization RatioAsset Util.
0.270.280.300.310.300.310.300.300.450.450.450.450.460.470.480.480.480.480.480.48
Leverage & Solvency
Interest Coverage RatioInterest Cover
3.502.490.802.711.941.842.832.832.331.802.822.792.42-1.491.721.721.35-7.661.883.15
Debt Ratio
0.390.370.340.340.320.330.330.330.330.340.330.350.340.350.330.330.340.310.320.32
Times Interest Earned
3.502.490.802.711.941.842.832.832.331.802.822.792.42-1.491.721.721.35-7.661.883.15
Valuation
Price to EarningsP/E
13.139.5212.8417.9124.5824.6318.0118.1711.4712.4212.6111.8915.6321.0521.8820.4218.9366.6081.5588.83
Price to SalesP/S
1.691.351.411.371.321.601.711.621.071.000.970.900.960.901.021.071.001.061.271.10
Price to BookP/B
1.110.930.970.960.881.061.091.041.030.950.920.840.891.021.040.971.021.271.09
Enterprise Value
44,797.39M34,679.90M38,148.96M37,621.24M33,244.27M42,146.22M47,999.69M45,510.25M44,733.37M41,218.32M40,841.88M33,715.64M37,155.02M36,228.87M44,609.99M44,443.53M39,544.38M42,715.29M54,961.83M45,313.74M
EV to EBIT
6.954.944.905.706.548.2611.3310.587.077.007.106.036.638.039.739.278.1416.1320.1916.72
EV to EBITDA
3.832.852.882.924.175.254.933.953.793.783.183.493.804.654.534.025.597.316.23
Market Capitalization
53,061.22M42,972.34M45,315.72M44,429.66M41,043.64M49,366.29M52,152.47M49,715.74M48,956.24M45,158.73M43,959.60M40,953.00M45,004.00M41,902.45M47,314.85M49,192.17M46,583.02M49,605.82M58,939.12M51,014.80M
Price to FCFP/FCF
6.275.997.146.846.938.608.158.2610.4511.669.699.376.648.388.207.037.6310.029.81
EV to FCF
5.295.046.055.545.927.917.467.559.5410.837.987.745.747.917.415.976.579.358.71
EV to CFO
4.713.594.094.745.166.716.356.447.838.306.316.354.916.416.044.925.387.907.23
Return Ratios
Return on Sales [ROS]ROS
26.17%12.92%25.56%15.48%10.42%13.40%15.93%15.92%12.51%8.43%13.96%13.77%11.83%-7.11%15.28%16.68%11.97%-38.03%16.51%16.51%
Return on Capital Employed [ROCE]ROCE
5.75%6.45%8.50%6.46%5.18%5.22%5.01%4.31%6.56%6.09%6.77%5.77%5.77%4.72%5.81%5.18%5.20%2.81%3.40%2.99%
Return on Invested Capital [ROIC]ROIC
7.03%7.83%9.11%7.98%6.33%6.42%5.24%5.27%7.82%7.24%7.06%6.70%5.77%6.07%6.05%3.29%3.45%3.48%
Return on Assets [ROA]ROA
3.52%4.04%4.44%3.57%2.89%3.24%2.81%2.64%4.23%3.63%3.48%3.43%2.84%2.01%2.26%2.51%2.54%0.76%0.74%0.60%
Return on Equity [ROE]ROE
8.59%9.64%10.43%8.11%6.37%7.07%6.15%5.73%8.97%7.65%7.28%7.14%4.62%5.14%5.16%1.54%1.52%1.24%

Takeda Pharmaceutical Ratios API

Pull Takeda Pharmaceutical's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TAK&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY